IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0012608
(2011-01-24)
|
등록번호 |
US-8492159
(2013-07-23)
|
발명자
/ 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
Wilson Sonsini Goodrich & Rosati
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
18 |
초록
▼
The invention relates to compositions comprising of SEQ NO: 1-244, 248-249, and any homologs, analogs, and fragments thereof. Such compositions can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions
The invention relates to compositions comprising of SEQ NO: 1-244, 248-249, and any homologs, analogs, and fragments thereof. Such compositions can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically or for systemic use.
대표청구항
▼
1. A method for identifying an analog of a polypeptide, wherein the polypeptide has a sequence consisting of SEQ ID NO: 1, the method comprising screening a library of candidate agents to identify a candidate agent having similar structure or function as the polypeptide, wherein the screening compri
1. A method for identifying an analog of a polypeptide, wherein the polypeptide has a sequence consisting of SEQ ID NO: 1, the method comprising screening a library of candidate agents to identify a candidate agent having similar structure or function as the polypeptide, wherein the screening comprises performing a binding assay using the library of candidate agents. 2. The method of claim h wherein the screening comprises analyzing an effect of the candidate agent on a binding interaction between a binding partner of the polypeptide and the polypeptide. 3. The method of claim 1, wherein the method further comprises performing high throughput screening of the library of candidate agents. 4. The method of claim 2, wherein the analyzing comprises analyzing a collection of candidate agents. 5. The method of claim 1, wherein the candidate agent is a small molecule having a molecular weight of less than 104 daltons. 6. The method of claim 4, wherein each member of the collection of candidate agents is administered to a plurality of samples, wherein each sample of the plurality of samples comprises the polypeptide and the binding partner of the polypeptide prior to the analyzing step. 7. The method of claim 2, wherein the binding partner of the polypeptide is immobilized on a solid support. 8. The method of claim 1, wherein the candidate agent is a synthetic agent. 9. The method of claim 7, wherein the solid support is a test well, a microtiter plate, a membrane, a bead, glass, or a disc. 10. The method of claim 1, wherein the analyzing step further comprises comparing a level of binding of the candidate agent to the binding partner of the polypeptide in the presence and absence of the polypeptide. 11. The method of claim 2, wherein the analyzing comprises determining competitive inhibition by the candidate agent of the binding interaction between the polypeptide and the binding partner of the polypeptide. 12. The method of claim 2, wherein the analyzing step comprises comparing a level of binding of the polypeptide to the binding partner of the polypeptide in the presence and absence of the candidate agent. 13. The method of claim 12, wherein the level of binding of the polypeptide is detected using a reagent that specifically binds to the polypeptide or using a detectable portion of the polypeptide. 14. The method of claim 13, wherein the detectable portion comprises a label. 15. The method of claim 1, wherein the candidate agent comprises a peptide or polypeptide. 16. The method of claim 15, wherein the candidate agent that comprises a peptide or polypeptide comprises at least one amino acid other than the 20 naturally occurring amino acids. 17. The method of claim 1, wherein the analog is a mimetic or peptidomimetic. 18. The method of claim 17, wherein the mimetic is a structural mimetic. 19. The method of claim 1, wherein the analog comprises nucleic acid. 20. The method of claim 1, wherein the library of candidate agents is a synthetic combinatorial library. 21. The method of claim 2, wherein the binding partner of the polypeptide comprises an antibody. 22. The method of claim 2, wherein the binding partner of the polypeptide comprises a receptor. 23. The method of claim 2, wherein the binding partner of the polypeptide is recombinantly produced. 24. The method of claim 2, wherein the binding interaction between the polypeptide and the binding partner of the polypeptide has an affinity binding constant of greater than or equal to 105 M−1.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.